Starling Oncology, Inc. - 8-K Filing
Starling Oncology reports Q3 2026 revenue of $169.8 million and updates full-year guidance with lowered Adjusted EBITDA and Free Cash Flow expectations. (Items: 2.02 Results of Operations and Financial Condition On November 5, 2026, Starling Oncology, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $DFPH
Read the full article at SEC EDGAR
Part of the story SHENANDOAH TELECOMMUNICATIONS CO/VA/ - 8-K Filing (57 articles)